The eye's intricate anatomical barriers pose significant challenges to the penetration,
residence time, and bioavailability of topically applied medications, particularly in managing …

Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical
industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the …

To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex®, as an
adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were …

Introduction To evaluate real-life efficacy, safety, and treatment patterns with the
dexamethasone intravitreal implant (DEX) in posterior segment inflammation due to non …

Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors
(CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated …

Purpose The present study aimed to assess the efficacy and safety associated to the
treatment of patients with non-infectious posterior uveitis with intravitreal dexamethasone …

We present retrospective data from our clinical research efforts of the past several years
alongside a review of past and current clinical and preclinical data independently by several …

Checkpoint inhibition targeting programmed cell-death protein 1 has demonstrated efficacy
for a wide range of indications including cutaneous malignancy. However, immune-related …

Macular edema (ME) is a common cause of visual loss among eyes with uveitis, and its
management can be challenging. Steroids are an effective treatment for ME, and intravitreal …

AIM To evaluate the long-term results of patients with chronic uveitis-induced cataract by
phacoemulsification with IOL implantation and intravitreal injection of dexamethasone (DEX) …